Ga Syfovre denied for missing prior authorization by Aetna?

Aetna's specific coverage criteria for ga syfovre are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Requires Prior Authorization for Syfovre — and How to Navigate It

Syfovre (pegcetacoplan) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) is subject to prior authorization (PA) by Aetna before the drug will be covered. This is a prospective coverage requirement — not a permanent denial — meaning coverage will be granted if the clinical documentation satisfies Aetna's criteria. When a PA is denied rather than simply pending, it means Aetna reviewed the submitted information and determined it did not meet one or more of its Clinical Policy Bulletin requirements.

## Why This Denial Is Appealable

A PA denial is a coverage determination and is subject to the same full appeal rights as any other denial. In many cases, PA denials for FDA-approved drugs are the result of incomplete documentation submitted in the initial request. A well-prepared appeal with complete clinical documentation resolves the gap and results in approval.

## Federal Appeal Rights

• ACA §2719 / ERISA §503: Prior authorization denials are subject to mandatory internal appeal rights. You are entitled to the specific criteria used in the denial decision.
• Expedited Prior Authorization: If the standard PA timeline would result in serious jeopardy to health or vision, you have the right to request expedited review, with a decision typically required within 72 hours.
• External Review: If the internal appeal of a PA denial is upheld, you may request an Independent Review Organization (IRO) review. The standard external review window is approximately four months from the final internal denial.
• Surprise Billing and Continuity Protections: If treatment has begun and authorization lapses, ask Aetna about continuity-of-care provisions.

## Appeal Timeline

1. Obtain the PA denial letter with the specific unmet criteria identified. 2. Contact your retina specialist's office to gather the documentation below. 3. Submit the internal appeal — many practices have a dedicated PA team that can manage this process. 4. Request expedited review if the delay poses a threat to vision.

## Documentation to Gather

• Diagnosis confirmation: Retinal imaging (FAF, OCT, fundus photography) confirming GA secondary to AMD with lesion location and size documented.
• Clinical severity documentation: Chart notes documenting GA progression rate and proximity of the lesion to the center of vision.
• Prior-treatment history: Documentation of any prior ocular therapies, their outcomes, and the rationale for now initiating Syfovre.
• Prescriber medical-necessity letter: A letter from your retina specialist addressing every criterion in Aetna's Clinical Policy Bulletin for Syfovre, citing the specific chart finding that satisfies each one, and confirming on-label use consistent with the FDA-approved prescribing information.

## Criteria-Mapping Strategy

Download the current Aetna Clinical Policy Bulletin for Syfovre or intravitreal pegcetacoplan. Create a two-column checklist: policy criterion on the left, the specific chart document and finding on the right. Submit this as the cover sheet of your appeal package. The prescriber letter should follow the same structure. Confirm that the exact diagnosis code on the PA request matches the GA indication in the FDA-approved label. If the policy references applicable professional society guidelines, ask your prescriber to confirm in writing that the care aligns with those guidelines — citing the organization by name without quoting specific numeric thresholds.